These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Pituitary adenylate cyclase activating polypeptide receptors are present on small cell lung cancer cells.
    Author: Moody TW, Zia F, Makheja A.
    Journal: Peptides; 1993; 14(2):241-6. PubMed ID: 8387187.
    Abstract:
    The effect of pituitary adenylate cyclase activating polypeptide (PACAP) on small cell lung cancer (SCLC) cells was investigated. In Fura 2-AM loaded NCI-N417 cells, PACAP-27 or PACAP-38 elevated cytosolic calcium in a dose-dependent manner. The cytosolic calcium was elevated from 133 to 185 nM with PACAP-27 (100 nM). Because PACAP-27 strongly elevated cytosolic calcium after the addition of 1 mM EGTA, PACAP released calcium from intracellular pools using NCI-N417 cells; similar results were obtained for SCLC cell line NCI-H345. Pituitary adenylate cyclase activating polypeptide-27 inhibited 125I-VIP and 125I-PACAP binding to NCI-N417 cells with high affinity (IC50 = 30 and 5 nM), whereas VIP inhibited 125I-VIP and 125I-PACAP-27 binding with IC50 values of 5 and 200 nM. Both 100 nM VIP and PACAP-27 elevated cAMP levels in NCI-H345 cells. In contrast, 1 microM VIP had no effect on cytosolic calcium, whereas 100 nM PACAP-27 caused a strong calcium response. Both 100 nM VIP and 10 nM PACAP-27 significantly stimulated the clonal growth of NCI-H345 cells. These data suggest that biologically active VIP and PACAP receptors are present on SCLC cells.
    [Abstract] [Full Text] [Related] [New Search]